Clustering of metabolic abnormalities among obese patients and mortality after percutaneous coronary intervention

American Journal of Cardiology

Volumn 107, Issue 10, 2011, Pages 1415-1420

  Bashey, Sameer ^a   Muntner, Paul ^b   Kini, Annapoorna S ^a   Esquitin, Ricardo ^a   Razzouk, Louai ^a   Mathewkutty, Shiny ^a   Wildman, Rachel P ^c   Carson, April P ^b   Kim, Michael C ^a   Moreno, Pedro R ^a   Sharma, Samin K ^a   Farkouh, Michael E ^a,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CLUSTER ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; OBESITY; TRIGLYCERIDES;

EID: 79955615257     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.01.012     Document Type: Article

References (30)

1. C.J. Lavie, R.V. Milani, and H.O. Ventura Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss J Am Coll Cardiol 53 2009 1925 1932
2. O.C. Marroquin, K.E. Kip, D.E. Kelley, B.D. Johnson, L.J. Shaw, C.N. Bairey Merz, B.L. Sharaf, C.J. Pepine, G. Sopko, and S.E. Reis Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation Circulation 109 2004 714 721 (Pubitemid 38222889)
3. C.A. Daly, P. Hildebrandt, M. Bertrand, R. Ferrari, W. Remme, M. Simoons, and K.M. Fox Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial Heart 93 2007 1406 1411 (Pubitemid 351480141)
4. T. Dohi, K. Miyauchi, T. Kasai, K. Kajimoto, N. Kubota, H. Tamura, T. Yokoyama, T. Kojima, K. Yokoyama, T. Kurata, and H. Daida Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome Circ J 73 2009 1454 1458
5. L. Gruberg, N.J. Weissman, R. Waksman, S. Fuchs, R. Deible, E.E. Pinnow, L.M. Ahmed, K.M. Kent, A.D. Pichard, W.O. Suddath, L.F. Satler, and J. Lindsay Jr The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 39 2002 578 584 (Pubitemid 34158151)
6. H.S. Gurm, P.L. Whitlow, and K.E. Kip The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization Insights from the Bypass Angioplasty Revascularization Investigation (BARI) J Am Coll Cardiol 39 2002 834 840 (Pubitemid 34185331)
7. L. Mehta, W. Devlin, P.A. McCullough, W.W. O'Neill, K.A. Skelding, G.W. Stone, J.A. Boura, and C.L. Grines Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction Am J Cardiol 99 2007 906 910 (Pubitemid 46483277)
8. H.S. Gurm, D.M. Brennan, J. Booth, J.E. Tcheng, A.M. Lincoff, and E.J. Topol Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox) Am J Cardiol 90 2002 42 45 (Pubitemid 34671201)
9. C.J. Lavie, and R.V. Milani Obesity and cardiovascular disease: the Hippocrates paradox? J Am Coll Cardiol 42 2003 677 679 (Pubitemid 37000184)
10. T. Lancefield, D.J. Clark, N. Andrianopoulos, A.L. Brennan, C.M. Reid, J. Johns, M. Freeman, K. Charter, S.J. Duffy, A.E. Ajani, J. Proietto, and O. Farouque Is there an obesity paradox after percutaneous coronary intervention in the contemporary era?: an analysis from a Multicenter Australian Registry JACC Cardiovasc Interv 3 2010 660 668
11. S. Kenchaiah, J.C. Evans, D. Levy, P.W. Wilson, E.J. Benjamin, M.G. Larson, W.B. Kannel, and R.S. Vasan Obesity and the risk of heart failure N Engl J Med 347 2002 305 313 (Pubitemid 34815352)
12. D. Hasdai, K.N. Garratt, D.E. Grill, A. Lerman, and D.R. Holmes Jr Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization N Engl J Med 336 1997 755 761 (Pubitemid 27113969)
13. A. Romero-Corral, V.M. Montori, V.K. Somers, J. Korinek, R.J. Thomas, T.G. Allison, F. Mookadam, and F. Lopez-Jimenez Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies Lancet 368 2006 666 678 (Pubitemid 44223694)
14. F. Lauretani, C.R. Russo, S. Bandinelli, B. Bartali, C. Cavazzini, A. Di Iorio, A.M. Corsi, T. Rantanen, J.M. Guralnik, and L. Ferrucci Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia J Appl Physiol 95 2003 1851 1860 (Pubitemid 37310367)
15. R. Roubenoff Sarcopenia and its implications for the elderly Eur J Clin Nutr 54 suppl 3 2000 S40 S47
16. B.A. Steinberg, C.P. Cannon, A.F. Hernandez, W. Pan, E.D. Peterson, and G.C. Fonarow Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database Am J Cardiol 100 2007 1331 1335 (Pubitemid 47576007)
17. W.B. Batchelor, K.J. Anstrom, L.H. Muhlbaier, R. Grosswald, W.S. Weintraub, W.W. O'Neill, and E.D. Peterson Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians J Am Coll Cardiol 36 2000 723 730
18. M. Bluher The distinction of metabolically "healthy" from "unhealthy" obese individuals Curr Opin Lipidol 21 2010 38 43
19. R.P. Wildman, P. Muntner, K. Reynolds, A.P. McGinn, S. Rajpathak, J. Wylie-Rosett, and M.R. Sowers The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 19992004) Arch Intern Med 168 2008 1617 1624
20. P.W. Serruys, P. de Feyter, C. Macaya, N. Kokott, J. Puel, M. Vrolix, A. Branzi, M.C. Bertolami, G. Jackson, B. Strauss, and B. Meier Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222 (Pubitemid 34686102)
21. A.W. Chan, D.L. Bhatt, D.P. Chew, M.J. Quinn, D.J. Moliterno, E.J. Topol, and S.G. Ellis Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696 (Pubitemid 34157371)
22. S.G. Ellis, D. Chew, A. Chan, P.L. Whitlow, J.P. Schneider, and E.J. Topol Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy Circulation 106 2002 1205 1210 (Pubitemid 34988637)
23. R. Merla, N.K. Reddy, F.W. Wang, B.F. Uretsky, A. Barbagelata, and Y. Birnbaum Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis Am J Cardiol 100 2007 770 776 (Pubitemid 47268265)
24. A.W. Chan, D.L. Bhatt, D.P. Chew, J. Reginelli, J.P. Schneider, E.J. Topol, and S.G. Ellis Relation of inflammation and benefit of statins after percutaneous coronary interventions Circulation 107 2003 1750 1756 (Pubitemid 36418355)
25. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 2004 674 678 (Pubitemid 39056265)
26. C. Briguori, G. Visconti, A. Focaccio, B. Golia, A. Chieffo, A. Castelli, M. Mussardo, M. Montorfano, B. Ricciardelli, and A. Colombo Novel Approaches for Preventing or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial Infarction J Am Coll Cardiol 54 2009 2157 2163
27. J. Lindsay, A.K. Sharma, D. Canos, M. Nandalur, E. Pinnow, S. Apple, G. Ruotolo, M. Wijetunga, and R. Waksman Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C Cardiovasc Revasc Med 8 2007 15 20 (Pubitemid 46216178)
28. S. Lavi, M. Kapeliovich, L. Gruberg, A. Roguin, M. Boulos, E. Grenadier, S. Amikam, W. Markiewicz, R. Beyar, and H. Hammerman Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: impact on long-term prognosis Int J Cardiol 123 2008 117 122 (Pubitemid 350250888)
29. S.P. Marso, K.H. Mak, and E.J. Topol Diabetes mellitus: biological determinants of atherosclerosis and restenosis Semin Interv Cardiol 4 1999 129 143
30. R.A. Corpus, P.B. George, J.A. House, S.R. Dixon, S.C. Ajluni, W.H. Devlin, G.C. Timmis, M. Balasubramaniam, and W.W. O'Neill Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention J Am Coll Cardiol 43 2004 8 14 (Pubitemid 38045906)